PT  - JOURNAL ARTICLE
AU  - Martin, Florence Z
AU  - Ahlqvist, Viktor H
AU  - Madley-Dowd, Paul
AU  - Lundberg, Michael
AU  - Cohen, Jacqueline M
AU  - Furu, Kari
AU  - Rai, Dheeraj
AU  - Forbes, Harriet
AU  - Easey, Kayleigh
AU  - Håberg, Siri E
AU  - Sharp, Gemma C
AU  - Magnusson, Cecilia
AU  - Magnus, Maria C
TI  - Antidepressant use during pregnancy and birth outcomes: analysis of electronic health data from the UK, Norway, and Sweden
AID  - 10.1101/2024.10.30.24316340
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.30.24316340
4099  - http://medrxiv.org/content/early/2024/10/30/2024.10.30.24316340.short
4100  - http://medrxiv.org/content/early/2024/10/30/2024.10.30.24316340.full
AB  - Objectives To explore the association between antidepressant use during pregnancy and birth outcomes.Design Cohort study.Setting Electronic health record data.Participants 2 528 916 singleton births from the UK’s Clinical Practice Research Datalink (1996-2018), Norway’s Medical Birth Registry (2009-2020), and Sweden’s Medical Birth Register (2006-2020).Main outcome measures Stillbirth, neonatal death, pre- and post-term delivery, small and large for gestational age, and low Apgar score five minutes post-delivery.Results A total of 120 209 (4.8%) deliveries were exposed to maternal antidepressant use during pregnancy. Maternal antidepressant use during pregnancy was associated with increased odds of stillbirth (adjusted pooled OR (aOR) 1.16, 95% CI 1.05 to 1.28), preterm delivery (aOR 1.26, 95% CI 1.23 to 1.30), and Apgar score < 7 at 5 minutes (aOR 1.83, 95% CI 1.75 to 1.91). These findings persisted in the discordant sibling analysis, but with higher uncertainty. The adjusted predicted absolute risk for stillbirth was 0.34% (95% CI 0.33 to 0.35) among the unexposed and 0.40% (95% CI 0.36 to 0.44) in the antidepressant exposed. Restricting to women with depression or anxiety, the association between antidepressant exposure and stillbirth attenuated (aOR 1.07, 95% CI 0.94 to 1.21). Paternal antidepressant use was modestly associated with preterm delivery and low Apgar score. Most antidepressants were associated with preterm delivery (except paroxetine) and Apgar score (except mirtazapine and amitriptyline).Conclusions Maternal antidepressant use during pregnancy may increase the risk of stillbirth, preterm delivery, and low Apgar score, although the absolute risks remained low. Confounding by severity of indication cannot be ruled out, as the severity of symptoms was not available. The modest association between paternal antidepressant use and both preterm delivery and low Apgar score suggests that residual confounding by familial environment cannot be ruled out.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the Research Council of Norway through its Centres of Excellence funding scheme (project number 262700), and the European Research Council through the Horizon 2020 research and innovation program (INFERTILITY, grant number 947684). FZM was supported by the Wellcome Trust (Grant ref: 218495/Z/19/Z). DR and HF acknowledge support from the NIH (1R01NS107607). GCS was supported by a Medical Research Council (MRC) grant (MR/S009310/1). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, MRC, or the Wellcome Trust. FZM, PM-D, VHA, KEE, GCS, DR, and MCM are members of the UK MRC Integrative Epidemiology Unit, which is funded by the MRC (MC_UU_00011/1, MC_UU_00011/3 and MC_UU_00011/7) and the University of Bristol.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by CPRD's Independent Scientific Advisory Committee (ISAC) [ISAC number: 21_000362] in the UK, the Swedish Ethical Review Authority in Sweden [DNR: 2020-05516], and the Committee for Medical and Health Research Ethics of South/East Norway [2017/2546/REK sor-ost A]. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAccess to CPRD data, including UK Primary Care Data, and linked data such as Hospital Episode Statistics, is subject to protocol approval as per CPRD's guidelines. Authors are unable to share the data in its raw form, however all analytical code and codelists are open-source and found via the following links: https://github.com/flozoemartin/Birth-outcomes and https://github.com/flozoemartin/codelists. https://github.com/flozoemartin/Birth-outcomes https://github.com/flozoemartin/codelists